REV1 and lymphoma: To examine whether REV1 is required in tolerating cisplatin lesions in cancer cells, we genetically ablated Rev1 in murine lymphoma cells that were described previously (18) using the same CRISPR/Cas9 targeting strategy as used for the Rev1-KO mice.